newsfilter
← Latest News
Business Wire·

Vasomune Therapeutics Appoints Meenu Chhabra to its Board of Directors

TORONTO--(BUSINESS WIRE)--Vasomune Therapeutics, Inc., an early stage therapeutic biopharmaceutical company developing a novel first-in-class medicine for the treatment of COVID-19/pathogen-induced ARDS, today announced the appointment of Meenu Chhabra to the Company’s Board of Directors. Ms. Chhabra is the President and Chief Executive Officer of Proteostasis Therapeutics, Inc. (NASDAQ:PTI).